| 3.47 0.07 (2.06%) | 11-04 15:59 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 5.9 | 1-year : | 7.2 |
| Resists | First : | 5.05 | Second : | 6.17 |
| Pivot price | 3.69  |
|||
| Supports | First : | 3.26 | Second : | 2.71 |
| MAs | MA(5) : | 3.52 |
MA(20) : | 3.8 |
| MA(100) : | 4.07 |
MA(250) : | 50.94 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 5.2 |
D(3) : | 6.6 |
| RSI | RSI(14): 46.1 |
|||
| 52-week | High : | 187.5 | Low : | 2.13 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BNBX ] has closed above bottom band by 33.3%. Bollinger Bands are 16.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.56 - 3.59 | 3.59 - 3.6 |
| Low: | 3.21 - 3.24 | 3.24 - 3.26 |
| Close: | 3.36 - 3.4 | 3.4 - 3.43 |
Applied DNA Sciences, Inc., a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment develops and commercializes the LinearDNA platform, which enables a cell-free manufacture of high-fidelity synthetic DNA sequences for use in nucleic acid-based therapeutics. The MDx Testing Services segment provides clinical molecular diagnostics (MDx) testing and clinical laboratory testing services; COVID-19 testing services, including test scheduling, sample collection, and automated results reporting for higher education institutions, private clients, and businesses under the safeCircle trademark; polymerase chain reaction (PCR) for production and detection of DNA and RNA; and MDx test kits and related supplies, as well as Isotopic analysis testing services. The DNA Tagging and Security Products and Services segment offers SigNature Molecular Tags, which provides a methodology to authenticate goods within large and complex supply chains for materials, such as cotton, nutraceuticals, and other products; SigNify portable DNA readers and SigNify consumable reagent test kits; and fiberTyping, which uses PCR-based DNA detection to detect a product's naturally occurring DNA sequences for the purposes of product provenance authentication and supply chain security. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. The company was founded in 1983 and is headquartered in Stony Brook, New York.
Wed, 26 Jul 2023
Stader Labs Review 2025 - Pros, Cons, Features, & Fees - Milk Road
Thu, 23 Feb 2023
Stader Labs (SD): Liquid Staking Across Chains - Bybit Learn
Wed, 29 Jun 2022
Binance Coin (BNB) vs Ripple (XRP): Comparative Analysis - CoinDCX
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 0 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 1.29e+006 (%) |
| Held by Institutions | 1.1 (%) |
| Shares Short | 108 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.308e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 213.5 % |
| Return on Equity (ttm) | -64.1 % |
| Qtrly Rev. Growth | 3.74e+006 % |
| Gross Profit (p.s.) | -273.85 |
| Sales Per Share | -1054.24 |
| EBITDA (p.s.) | 9.61539e+006 |
| Qtrly Earnings Growth | -57.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0.05 |
| Dividend | 0 |
| Forward Dividend | 401430 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|